Endocannabinoid system enzymes MAGL and FAAH show promise as targets for treating Alzheimer's-related cognitive decline | Research

The takeaway

Blocking the enzymes that break down endocannabinoids may protect neurons from amyloid damage, reduce tau phosphorylation, and improve learning and memory in Alzheimer's models.

People interested in Alzheimer's research, neuroscience enthusiasts, those following endocannabinoid system therapeutics

MAGL and FAAH inhibitors target multiple Alzheimer's mechanisms simultaneously

What the researchers found

MAGL and FAAH inhibitors have shown potential to protect neurons from amyloid-beta toxicity, reduce tau phosphorylation, combat oxidative stress, and stimulate neurotrophins that support brain repair. These effects have been demonstrated across multiple preclinical Alzheimer's models.

Why it matters

Current Alzheimer's treatments target single pathways and have limited efficacy. Endocannabinoid-modulating drugs could address multiple disease mechanisms simultaneously, potentially offering a more comprehensive treatment approach.

The numbers in context

MAGL degrades 2-AG; FAAH degrades AEA; both enzyme types have been studied across multiple Alzheimer's disease models

How the study worked

Narrative review summarizing preclinical studies on MAGL and FAAH inhibitors in Alzheimer's disease models, including their effects on neurodegeneration, inflammation, and cognitive function.

What this study cannot tell us

Nearly all evidence comes from animal models. No MAGL or FAAH inhibitors have been tested in human Alzheimer's trials. The exact signaling mechanisms are not fully understood. Translation from preclinical to clinical efficacy is uncertain.

How to read the evidence

Narrative review of preclinical studies with no human clinical trial data

When this study was published

Published in 2021. Endocannabinoid-based Alzheimer's therapeutics remain in early research stages.

The bigger picture

The endocannabinoid system's involvement in neuroinflammation, neuroprotection, and synaptic plasticity makes it an increasingly studied target for neurodegenerative diseases beyond Alzheimer's, including Parkinson's and multiple sclerosis.

Questions still open

Will MAGL and FAAH inhibitors prove safe and effective in human Alzheimer's trials? Could these compounds complement existing Alzheimer's treatments? At what disease stage would endocannabinoid modulation be most effective?

Common questions

Could endocannabinoid-based drugs treat Alzheimer's?

Preclinical studies show promise. Inhibitors of MAGL and FAAH, enzymes that break down natural endocannabinoids, have protected neurons and improved memory in animal models. Human trials have not yet been conducted.

How would these drugs work differently from current Alzheimer's treatments?

Unlike current treatments that target single pathways, MAGL and FAAH inhibitors appear to address multiple disease mechanisms, including amyloid toxicity, tau phosphorylation, oxidative stress, and neuroinflammation.

Read the original research

The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?

Brain research bulletin, 174, 305-322

View on PubMed ↗Publisher’s paper ↗

Citation

Bajaj, Shivanshu; Jain, Shreshta; Vyas, Preeti; Bawa, Sandhya; Vohora, Divya. (2021). The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?. Brain research bulletin, 174, 305-322. https://doi.org/10.1016/j.brainresbull.2021.06.022